Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 1;19(4):469-474.
doi: 10.1093/neuonc/nox030.

Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma

Stuart A Grossman  1 , Karisa C Schreck  1 , Karla Ballman  2 , Brian Alexander  3
Affiliations

Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma

Stuart A Grossman et al. Neuro Oncol. .
No abstract available

Keywords: clinical trials; newly diagnosed glioblastoma; phase II; randomized; single-arm.

PubMed Disclaimer

Comment in

References

    1. Gehan EA, The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J.Chronic Dis. 1961;13:346–353. - PubMed
    1. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38(1):143–151. - PubMed
    1. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10. - PubMed
    1. Sargent DJ, Chan V, Goldberg RM. A three-outcome design for phase II clinical trials. Control Clin Trials. 2001;22(2):117–125. - PubMed
    1. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics. 1995;51(4):1372–1383. - PubMed

MeSH terms